Hantavirus vaccine in 2026?
6%
Real price history (past month), from Polymarket. Down-sampled to 24 points.
What the market is pricing
The market is pricing this at single-digit, unlikely odds, reflecting the rarity of vaccine approvals in a compressed timeline. The probability has remained unchanged over the past week, suggesting stable skepticism about the prospect of full FDA clearance within roughly two years. At this probability level, the market is treating an approved Hantavirus vaccine by end-2026 as a low-likelihood outcome.
How this market resolves
This market resolves Yes if any human Hantavirus vaccine—covering Hantavirus Pulmonary Syndrome or Hemorrhagic Fever with Renal Syndrome—receives full FDA approval by December 31, 2026. Otherwise it resolves No.
| Implied probability (Yes) | 6% |
|---|---|
| 24h change | +0 pt |
| 7d change | +0 pt |
| Market volume | $128K |
| Resolves by | 2026-12-31 |
| Source | Polymarket ↗ · as of 2026-07-10 |
What could move it
- Any announcement of FDA approval—full or emergency—would settle the market immediately in the Yes direction; absence of approval news favors No as the deadline approaches.
- Thin time remaining before the December 2026 close limits opportunity for major shifts; clinical trial results or regulatory decisions between now and late 2026 are the main levers.
This is an implied probability from a real-money prediction market (Polymarket), shown as information — not a forecast we endorse and not financial or trading advice. Markets can be thin or move fast; always check the source. Odds ≠ advice.
